Hearing implant group Cochlear has increased its investment in a start-up business developing a device to combat obstructive sleep apnea.
Apnea, a market dominated by Cochlear’s Australian rival ResMed, has attracted a number of competing devices with healthcare company Nyxoah pursuing a novel approach.
The company’s device (pictured) stimulates the tongue nerve during sleep, triggering the nerve to contract the tongue.
A minimally invasive surgical procedure to implant a neurostimulator is part of the treatment.
Cochlear first invested 13 million Euros in Nyxoah in 2018 which has been revalued at $35.8 million.
Now the Sydney company has invested a further $13 million as part of a much larger round of funding.
Cochlear made the investments through its innovation fund.
Subscribe to our free @AuManufacturing newsletter here.